NewsBenzingaAtrium Therapeutics Doses First Patient In Its Phase 1/2 Corventis Clinical Trial Evaluating ATR 1072 For Potential Treatment Of PRKAG2 Syndrome; Expects Initial Proof-Of-Concept Data In H2 2027 Atrium Therapeutics Doses First Patient In Its Phase 1/2 Corventis Clinical Trial Evaluating ATR 1072 For Potential Treatment Of PRKAG2 Syndrome; Expects Initial Proof-Of-Concept Data In H2 2027 Benzinga 2026.10.27 10:38 (GMT+0) Open on Benzinga Other news New Address Withdraws 1.344 Billion PUMP From Coinbase, Worth About $3.87 Million Key Overnight and Morning News (November 16–17) Crypto Sectors Trade Mixed as DeFi Rises 1.67% While RWA and GameFi Each Drop Over 2% AI Lab Noeri, Founded by Stanford Professors, Raises $110M With Nvidia Among Investors Baidu Q3 Earnings: Total Revenue 30.8 Billion Yuan, AI Business Revenue Share Above Half for Third Straight Quarter Bitcoin, XRP, Dogecoin Slide, Ethereum Steady as ‘Extreme Fear’ Persists: Analyst Says ‘Selling Hasn’t Stopped Yet’ as Whales Offload BTC
Baidu Q3 Earnings: Total Revenue 30.8 Billion Yuan, AI Business Revenue Share Above Half for Third Straight Quarter
Bitcoin, XRP, Dogecoin Slide, Ethereum Steady as ‘Extreme Fear’ Persists: Analyst Says ‘Selling Hasn’t Stopped Yet’ as Whales Offload BTC